Q2 2011

Filed Apr 12, 2011 · 10-Q · 43 days after period end · 0001144204-11-021465

Q2 2011 · 10-Q

Revenue—

Net Income

-$642.79K

no prior Q2 2010 on file

EPS Diluted

$0.01

no prior Q2 2010 on file

Operating Income-$647,215—

Operating Cash Flowderived-$197,047—

Same quarter

no prior Q2 2010 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Feb 28, 2011 · filed Apr 12, 2011 · 43 d after period end

Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR